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 SUMMARY 
 
 Mycobacterium tuberculosis (MTB) is one of the world’s most successful 
pathogens; killing millions each year. Cofactors are generally required for essential 
functions and their biosynthesis is considered to be an attractive drug target. The focus of 
this master’s project is to understand the functional significance of coenzyme F420 (7,8-
didemethyl-8-hydroxy-5-deazaflavin derivative) in Mycobacterium bovis BCG through 
generation of an fbiC knock-out mutant and its characterisation under various 
physiologically-relevant in vitro conditions. Coenzyme F420 was first isolated from 
methanogenic archae and later identified in non-methanogenic archae also, a few Gram 
positive eubacteria and eukaryotes. In mycobacteria, F420 is involved in the oxidation of 
glucose-6-phosphate (J. Bact (1996); 178, 2861) and incidentally also involved in the 
activation of bicyclic 4-nitroimidazole PA-824 (Nature (2000); 405, 962). Most 
mycobacterial F420 work is driven by the study of the bioactivation of nitroimidazoles (J. 
Bact (2002); 184, 2420; Proc Natl Acad Sci U S A (2006); 103, 431 and Science (2008); 
322, 1392). In MTB, F420 is not essential for survival under in vitro aerobic conditions. 
All mycobacterial species studied to date have F420 or F420 biosynthetic genes including 
M. leprae. The maintenance of such complex biosynthetic pathways, even in M. leprae 
which has undergone substantial gene decay (Nature (2001); 409, 1007), strongly 
suggests that F420 plays a vital role in the biology of mycobacteria. 
  
 fbiC (Rv1173) encodes an 856-amino acid polypeptide which is an FO synthase 
responsible for the condensation of pyrimidinedione with hydroxyphenyl pyruvate, likely 
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 the first committed step in the F420 biosynthesis pathway (J. Bact (2002); 184, 2420; 
Arch. Microbiol. (2003); 180, 455). Using a forward genetics approach, an fbiC-KO 
mutant was generated in Mycobacterium bovis BCG. The mutation was confirmed by 
confirmatory PCR and Southern hybridisation. The knock-out mutant became resistant to 
PA-824 and also produced insignificant levels of cofactor F420 compared to wild type 
Mycobacterium bovis BCG cells. However, the complemented strain completely restored 
PA-824 sensitivity and F420 levels in the cell. Preliminary experiments revealed that the 
F420-deficient mutant was hypersensitive to nitric oxide (NO) and rendered low viability 
under hypoxic conditions, suggesting a possible role for F420 or a F420-dependent pathway 
in protection against nitrosative stress and survival under hypoxia in mycobacterium. 
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1.1 TB: Disease and epidemiology. 
Tuberculosis (TB) is regarded as one of the oldest of illnesses affecting 
mankind, and is now very widely accepted as a re-emerging infectious disease at its 
worst (Sacchettini et al., 2008; Smith, 2003). Historically, evidence of TB infections 
has been noted in record and its lethality well-acknowledged (Smith, 2003). 
Incidences of this disease have been reported even before Roman times by different 
names along the chronological timeline (Mathema et al., 2006; Smith, 2003).  
 
Currently, this ‘scourge of man’ ranks as the most devastating human 
pathogen, infecting around 2 billion individuals whilst killing an estimated 2 million 
per annum (Laughon, 2007). In areas where co-infection with human 
immunodeficiency virus (HIV) is prevalent i.e. South Africa, annual cases of TB-
related death are alarmingly high (Sacchettini et al., 2008; Laughon, 2007; Goletti et 
al., 2008; Corbett et al., 2003) and drug-based therapy is immensely challenged 
(Kaufmann, 2001). The epidemiological map in Figure 1.1 represents a very recent 






Figure 1.1 An epidemiological map of the global burden of TB (WHO report, 2008). 
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 1.2 TB: Basic microbiology 
The breakthrough discovery linking Mycobacterium tuberculosis (MTB) to 
TB was made by the German microbiologist Robert Koch in 1882 (Smith, 2003, 
Kaufmann, 2001). The genus mycobacterium belongs to Volume 2 and section 16 of 
Bergey's Manual of Systematic Bacteriology that comprises highly evolved, aerobic, 
non-motile, non-encapsulated, slender, phylogenetically Gram-positive but acid fast-
staining bacilli (due to cell wall-associated mycolic acids; Hett and Rubin, 2008). 
Mycobacteria are of immense public health importance as many pathogenic species 
belong to this group. The most widely recognised Mycobacterium species are M. 
tuberculosis, the aetiologic agent of tuberculosis and M. leprae, which causes the 
cutaneous and neural disorder known as leprosy. Besides these pathogens, M. avium 
(Toba et al., 1989), M. kansasii (Taillard et al., 2003), M. chelonae (Cooper et al., 
1989), M. marinum (American Thoracic Society statement, 1997) and M. fortuitum 
(Parti et al., 2005) can cause opportunistic infections in immuno-compromised hosts.  
 
MTB colonies that grow on mycobacterial solid medium (Middlebrook 7H11 
or 7H10) without detergent (Tween 80) appear morphologically distinct (flat, dry and 
‘fried-egg’ like appearance, Figure 1.2 (I)). The standard microbiological 
identification for the TB bacillus employs the Ziehl-Neelsen staining method (acid-
fast) and thus, the bacterium is also termed as acid-fast bacilli or simply AFB (Figure 
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Figure 1.2 I. Typical mycobacterial colony growing on Middlebrook 7H11 agar and 
without Tween 80. (Source: http://www.textbookofbacteriology.net/mtbcolonies.jpeg); II. 
Acid-fast stained mycobacteria (Source: 
http://people.uleth.ca/~selibl/Biol3200/Morphology04/MsAF.jpg.) 
 
1.3 TB: Pathology 
The contagion of tuberculosis is via inhalation of aerosols (about 1 - 5µm in 
diameter) containing TB bacilli produced by infected persons due to coughing or 
sneezing (Mathema et al., 2006). Following this, roughly 10% of inhaled TB bacilli 
reach the apical pulmonary sections where alveolar macrophages reside (Fenton and 
Vermeulen, 1996) and are ingested but not efficiently killed in every case (Warner 
and Mizrahi, 2007). This is more than sufficient to eventually establish infection 
(Kaufman, 2001).  As to whether the infection leads to severe clinical disease rather 
heavily rests on competency of the individual’s immune system to contain the 
dissemination of mycobacterial cells (Kaufmann, 2001). As a matter of fact, severity 
of disease in individuals with extremely weakened immunity i.e. AIDS patients, 
patients under immunosuppressant drugs and malnutrition has been reported 
extensively (Smith, 2003; Sacchettini et al., 2007; Pablos-Mendez et al., 1998; Cox et 
al., 2006).  
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 An important and noteworthy feature of the bacilli is that they prolifically 
replicate within alveolar macrophages. Mycobacterial replication within the 
macrophage will eventually lead to lysis of the host cell due to overwhelming 
bacterial load. Spillage of bacteria into the alveolar space would attract more 
macrophages, monocytes (undifferentiated macrophages) and other immune cells 
consequently infecting more of them (Smith, 2003). Although macrophages are 
equipped with efficient antimicrobial armament i.e. reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) to kill ingested bacteria, the cell wall physiology 
of mycobacteria is sufficiently equipped to circumvent this. From an evolutionary 
point of view, the bacillus has equipped itself with mechanisms of preventing 
intracellular bactericidal events i.e. formation of phagolysosomes - fusion of the 
phagosomal compartment (containing ingested bacilli) with the lysosome (Warner 
and Mizrahi, 2006) leading to killing of bacteria in which the complex, mycolic acid-
rich mycobacterial cell wall has been implicated (Smith, 2003) or simply virulence in 
general (Hotter et al., 2005).  
 
Less than 10% of infected individuals eventually develop clinical disease, due 
to containment by alveolar macrophages and a militia of immune cells. However, in 
clinical disease, lesions due to mycobacterial proliferation occur leading to the 
formation of alveolar cavities. Increasing cavity sizes can then allow the disease to 
progress to a state of high infectiousness (Kaufmann, 2001). Subsequently, clustering 
of recruited immune cells such as neutrophils, T cells and B cells culminate in the 
development of caseous granulomas (Connolly et al., 2007; Smith, 2003). Caseous 
(‘cheese-like’ appearance) granulomas are effectively necrotic lung tissue which, on 
the other hand provide a very hospitable and nutrient-rich (albeit oxygen-deficient) 
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 living environment for the pathogen (Kaufmann, 2001). Increasing bacterial load will 
permit spillage of bacilli into the lymphatic system, where accumulation of bacterial 
cells in regional lymph nodes will occur; clinically termed as miliary TB. This leads 
to swelling of the lymph nodes and exacerbates the severity of tuberculosis pathology 
(Smith, 2003; Mathema et al., 2006). Release of TB bacilli into the bloodstream 
(systemic infection) disseminates mycobacterial cells throughout the body, resulting 
in establishment of chronic extrapulmonary disease (or miliary TB). The various 
clinical manifestations observed and reported in this respect are associated with the 
central nervous system (tubercular meningitis), brain (tuberculomas or brain 
granulomas) urogenital tract (lupus vulgaris), bone (caused by hyper-inflammatory 
response) or even the gastro-intestinal system (Smith, 2003; Mitchison, 2005). 
 
Clinical manifestation of the disease is marked by symptoms such as 
prolonged and intense coughing, fevers, chills and night sweating. Progression of 
severe disease leads to coughing blood (haemoptysis), dramatic weight loss and 
lethargy (www.cdc.gov; de Souza, 2006).  Figure 1.3 very concisely summarises the 
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 Inhalation of infectious 
aerosol (containing MTB)




Establishment of localized 
disease (primary TB)
















Acute disease (meningitis, 
miliary TB) 
MFigure 1.3 Schematic representation of the disease process by chronological order. The 
straight lines represent a direct transition of the disease stage whereas the dotted lines 
represent the possibility of transition to the latter stage. (Source: Reinout et al., 2002. Clin. 
Microbiol. Rev. 15 (2); 294 – 309). .4 TB: Preventive measures 
As relevant to any disease, prevention is better than cure. In the case of TB, 
ue the very high contagiousness of the disease, vaccination has historically been 
dministered as a means of protection. The currently available form of TB vaccination 
s the only one in circulation, namely the Bacille-Calmette Guerin vaccine or simply 
CG. This was developed at the Pasteur Institute in Paris in 1921 (O’Donnell, 1997) 
y repeatedly passaging M. bovis BCG in a potato-dextrose broth medium over a long 
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 period of time (nearly 200 passages) to eventually obtain a live, attenuated strain.                        
Recently BCG vaccination has been shown to have a little protection against adult 
pulmonary TB, however it is quite effective in paediatric settings. Therefore, an 
effective method of prevention via vaccination is yet to avail itself.   
 
1.5 TB: Diagnostics and Chemotherapy 
The presumptive diagnosis of active pulmonary TB is often made on the basis 
of microscopic examination of a stained sputum smear for AFB (Mitchison, 2005) 
followed by confirmation of diagnosis by growth of MTB in culture and agar plates. 
Another commonly used test is the tuberculin test, a delayed type cellular 
hypersensitivity reaction, which involves intracutaneous injection of purified protein 
derivatives (PPD) of mycobacteria (Fenton and Vermeulen, 1996). A relatively 
nascent but powerful diagnostic technique currently in use is the QuantiFERON® 
method, developed by Cellestis Ltd., Australia. In brief, this test measures the release 
of IFN-γ in the patient’s blood stream and correlates a mounting inflammatory 
response against a specific, recognisable antigen to infection. This approach is also 
capable of detecting latent TB infections (LTBI), which is implicated in reactivation 
of disease under defined circumstances (Mazurek and Villarino, 2003; Ernst et al., 
2007). The need for specific and sensitive diagnostic methods for tuberculosis has 
spurred the development of polymerase chain reaction (PCR) based tests that bypass 
the requirement for growth of the organism. Amplification of 16S rRNA and IS6110 
sequences specific to MTB forms the basis of one of the procedures (Boshoff and 
Barry, 2005).  Clinical diagnostics of TB employs the use of chest X-rays to check for 
tubercles -large cavitary lesions in lungs of patients which may indicate the state of 
the disease (Mitchison, 2005). Active TB can be identified this way and the outcome 
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 may lead to commencement of treatment with first-line antitubercular drugs 
(www.cdc.gov).  
 
After 60 years of discovery of MTB, in 1944 Selman Waksman discovered 
Streptomycin, the first drug that was found to be specific against this organism 
(Sacchettini et al., 2008). Prior to this development, the use of sulfonamides and 
sanocrysin (an organic salt of gold) had been under way for several years (Mitchison, 
2005; Clarke, 1929). Following Streptomycin, a protein synthesis inhibitor, other new 
anti-tubercular agents were introduced as summarised in Table 1.1 (along with 
molecular targets and genetic basis of resistance). Because of the development of 
resistance to monotherapy, a combination of four drugs - Isoniazid (INH), Rifampicin 
(RMP), Pyrazinamide (PZA) and Ethambutol (EMB) are used to treat TB at present. 
The WHO DOTS (Directly observed treatment, short-course) programme involves an 
intensive phase of chemotherapy using all four drugs for the first two months, 
followed by a continuation phase of Isoniazid and Rifampicin over a further four 
months (Handbook of anti-tuberculosis agents, 2008). Aminoglycosides such as 
Capreomycin, Viomycin, Kanamycin and Amikacin, and the newer quinolones such 
as Ciprofloxacin, Moxifloxacin, etc., are also effective against mycobacteria but are 
used only in drug resistance situations. 
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 Drug (year*) Functions Target Molecular basis
affected molecules of resistance
Streptomycin (1944) Prokaryotic protein S12 ribosomal protein Point mutations in rpsL 
translation and 16S rRNA and rrs  locus
Isoniazid (1952) Fatty acid elongation Enoyl reductase and Mutation in KatG , inhA
and mycolic acid catalase peroxidase
biosynthesis
Pyrazinamide (1954) Change in the pH Amidase Mutations in pncA
Ethambutol (1962) Arabinogalactan Arabinosyl transferase Mutation in embA 
biosynthesis and embB
p- aminosalicylic acid (PAS) Folate synthesis, Folate synthase Mutations in thyA
iron uptake
Rifampicin (1963) Elongation of full β-subunit of Mutations in rpoB
length transcripts RNA polymerase















MasTable 1.1 Antibacterial drugs for tuberculosis chemotherapy. * Year introduced as an 
antitubercular agent.  
 B: Drug resistance  
Control of tuberculosis (TB) remains one of the most grave challenges to 
al health. In 2007 alone there were an estimated 9.2 million new cases and 2.5 
ion deaths (WHO, 2008). TB is predominantly a disease associated with poverty; 
 80% of cases usually occur in Asia or Africa. Despite the standard drug regimen 
lability in recent years, TB has returned to reality predominantly because of drug 
tance. The currently used first-line drugs are gradually becoming completely 
ective in treating TB infections due to drug resistance.  Resistance to at least the 
major first-line anti-tuberculosis drugs Isoniazid and Rifampicin has been termed 
idrug-resistant tuberculosis (MDR-TB). Treatment of MDR-TB requires 
onged and expensive chemotherapy using second-line drugs of increased toxicity 
w.who.int). 
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 As a result of efforts to treat MDR-TB with a lengthy and less effective 
regimen, the next frightening drug-resistant phenotype evolved - Extensively Drug 
Resistant TB (XDR-TB) (Gandhi et al., 2006) . XDR-TB was identified in 2007 as a 
major challenge to global health (Raviglione and Smith, 2007). Defined by resistance 
to Rifampin and Isoniazid, a fluoroquinolone (Moxifloxacin) and one of the second-
line injectable anti-TB agent (Amikacin, Kanamycin, or Capreomycin), the first 
cluster of XDR-TB was seen among AIDS patients in the KwaZulu-Natal Province of 
South Africa (Gandhi et al., 2006). The development of drug-resistant (MDR and 
XDR) MTB strains is predicated upon two mechanisms that augment artificial 
selection. Firstly, erroneous drug prescribing practices on the part of clinicians 
especially in countries where DOTS is not implemented. Secondly is inappropriate 
and irregular intake of the prescribed medications on the part of patients (non-
compliance). Thus, drug-resistant strains may arise in previously treated patients 
(acquired drug resistance) or may occur in naïve patients when resistant strains are 
transmitted (primary drug resistance). The prevalence of MDR-TB and XDR-TB is 
inversely correlated with the quality of TB programs, with the most important factor 
being proper use of first-line and second-line chemotherapeutic agents and their 
effectiveness (Matteelli et al., 2007). There is now an urgent need for discovery of 
new classes of antitubercular agents that target new metabolic pathways for tackling 
the emergence of MDR-TB and XDR-TB strains (Sassetti and Rubin, 2008; Andries 
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 1.7 Cofactors, an essential component of enzyme activity 
A fundamental role of proteins is to act as enzyme-catalysts that increase the 
rate of almost all chemical reactions within cells. In the absence of enzymatic 
catalysis, most biochemical reactions are so slow that they would not occur under the 
mild conditions of temperature and pressure compatible with life. Enzymes, in 
addition to binding to their substrates, bind to other small molecules called 
“cofactors” that participate in enzyme catalysis. Cofactors can be divided into two 
broad groups: coenzymes and prosthetic groups. Prosthetic groups form a permanent 
part of the protein structure for example haeme, many metal ions iron, molybdenum, 
zinc etc. In contrast, coenzymes are small organic non-protein molecules like NAD, 
NADP, FAD, FMN, Biotin etc that carry chemical groups (hydride, electron, methyl 
group, acetyl group etc) between enzymes. These molecules are generally not bound 
tightly by enzymes but released as a normal part of the catalytic cycle. Because of the 
critical roles played by these cofactors in many important enzymatic functions, 
inhibition of cofactor biosynthesis would have a broader impact on an array of 
metabolic pathways. Hence, cofactors in biosynthentic pathways are considered to be 
attractive drug target candidates (Begley 2006; Mack and Grill, 2006; Mdluli and 
Spigelman, 2006). Many TB drug development efforts involving cofactors as drug 
targets are underway: biosynthesis of NAD (Boshoff et al., 2008), pantothenate 
(Sambandamurthy et al., 2002; Wang and Eisenberg, 2002), folates (Huovinen et al., 
1995), biotin (Lin et al., 2006; Sacchettini et al., 2008) etc. Apart from these 
ubiquitous cofactors, mycobacteria also possess an unique deazaflavin called F420 (N-
(N-L-lactyl-γ-glutamyl)-L-glutamic acid phosphodiester of 7,8-didemethyl-8-
hydroxy-5-deazariboflavin 5’-phosphate). F420 has limited distribution among 
euryarchaea, halobacteria (Lin and White 1986), some cyanobacteria (Eker et al., 
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 1990) and in Gram-positive bacteria with high G+C content (McCormick and Morton, 
1982, Bair et al., 2001; Graupner and White, 2003).    
 
1.8 Cofactor F420 and cellular biochemistry 
 Coenzyme F420 is named as such for intense absorption at 420 nm at pH 7 in 
its oxidised form. F420 was first discovered in 1960 in Mycobacterium phlei as a 
“greenish-yellow coenzyme” that converts glucose-6-phosphate to 6-
phosphogluconolactone in the presence of a partially purified enzyme mixture (Sutton 
1964). Twelve years later, Cheeseman and coworkers isolated and described the 
properties of F420 from Methanobacterium sp. strain M.o.H (Cheeseman et al., 1972). 
The chromophore of F420 is a 7, 8-didemethyl-8-hydroxy-5-deazariboflavin which is 
linked to ribityl sugar at its N-10 position to form FO (7, 8-didemethyl-8-hydroxy-5-
deazariboflavin ribitol) (Figure 1.4). FO is covalently linked to phospholactate 
through a hydroxyl group on ribose sugar to form F420-0. Mature F420 in different 
organisms differs in the number of glutamate residues as well as the nature of peptide 
formed.  
 




















































Figure 1.4 Structure of cofactor F420 in Mycobacterium sp. 
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 The structures of coenzyme F420 in MTB, M. smegmatis, M. bovis and M. 
fortuitum have 5-6 glutamate residues with a γ-peptide bond (Bair et al., 2001). In 
Methanobacterium thermoautotrophicum and many other methanogenic bacteria, F420 
predominantly exists with two glutamate residues bound to F420-0 with the γ-peptide 
bond, however F420 present in Methanococcus jannaschii contains three glutamates; 
two as residues with the γ-peptide bond, which is capped with a third α- glutamate 
arm (Nocek et al., 2007). Despite the structural resemblance of F420 to flavin 
analogues, F420 is functionally similar to nicotinamide cofactors like NAD and NADP 
(Walsh, 1986). F420 is involved in hydride transfer reactions with a redox potential in 
the range of -340 to -350 mV (DiMarco et al., 1990). 
 
Unlike other NAD, NADP and flavins, F420 is not ubiquitous and has a unique 
distribution. It is present in methanogenic and non-methanogenic archaea, 
actinobacteria and some eukaryotes. In methanogenic archaea, F420 is required for 
several steps in the methane biosynthesis pathway (Jones et al., 1987). Several F420-
dependent enzymes have been characterised in methanogenic archaea so far: 
methylene-tetrahydromethanopterin dehydrogenases, methylene-
tetrahydromethanopterin reductase, formate dehydrogenase, F420-reducing 
hydrogenase and alcohol dehydrogenases (Aufhammer et al., 2004; Purwantini and 
Daniels, 1996; DiMarco et al., 1990). In non-methanogenic archaea F420 is found in 
Halobacterium, Thermoplasma, Sulfolobus and Archaeoglobus species (Lin and 
White, 1986). Among eubacteria, F420 is used by Streptomyces sp. for lincomycin and 
tetracycline biosynthesis (Coats et al., 1989; McCormick and Morton, 1982; Jones et 
al., 1987). Also in Streptomyces, as well as the green algae Scenedesmus, the 
deazaflavin ring of F420 is required for DNA photolyase function (Eker et al., 1990).  
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 In mycobacteria and nocardia, F420 is involved in the oxidation of glucose-6-
phosphate by an F420-dependent glucose-6-phosphate dehydrogenase (FGD1, Rv0407 
– MTB gene) which in-turn biochemically modifies F420 to its reduced form, H2F420 
(Purwantini and Daniels, 1996). Coincidentally, this reaction is required for the 
activation of bicyclic 4-nitroimidazoles (Stover et al., 2000, Matsumoto et al., 2006). 
Bicyclic nitroimidazoles like PA-824 and OPC-67683 are an interesting class of 
antitubercular compounds that have inhibitory activity against both actively 
replicating and hypoxic non-replicating MTB. They also show good activity against 
drug sensitive and MDR clinical strains. Both these drug candidates are currently in 
human phase 2 clinical trials (www.tballiance.org), and seem to have the potential to 
shorten the TB chemotherapy period. For the activation of nitroimidazoles, both the 
ability to produce F420 and subsequently reduce this deazaflavin with FGD1 are 
essential. Recently, an F420-dependent nitroreductase (Rv3547) has been identified 
(Manjunatha et al., 2006) and biochemically characterised (Singh et al., 2008). 
Rv3547 is an F420-dependent novel class nitroreductase which releases nitric oxide 
from PA-824. MTB has four homologues of this protein: Rv3547, Rv1558, Rv3178 
and Rv1261c. However, the physiological role of Rv3547 or any of its homologues 
are not known. In MTB, F420 is not essential for survival under in vitro aerobic 
conditions. All mycobacterial species studied to date have F420 biosynthetic genes 
including M. leprae.  The maintenance of such complex biosynthetic pathways, even 
in M. leprae which has undergone substantial gene decay (Cole et al., 2001), strongly 
suggests that F420 plays a vital role in the biology of mycobacteria. The physiological 
roles of F420 remain to be clarified.  
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 1.9 Literature survey of F420 biosynthetic pathway.  
Based on 14C labelled experiments in Methanobacterium 
thermoautotrophicum, it has been shown that the deazaflavin ring of F420 is 
synthesised from the riboflavin precursor 5-amino-6-ribitylamino-2,4(1H,3H)-
pyrimidinedione (Jaenchen et al., 1984; Reuke et al., 1992).  Condensation of 
pyrimidinedione with hydroxyphenylpyruvate (a precursor of L-tyrosine) is carried 
out by cofG and cofH homologues of methanococcus (Graham et al., 2003). cofG and 
cofH homologues correspond to N-terminal and C-terminal domains of FO synthase 
(fbiC, Rv1173 in MTB; Mb1206c in M. bovis BCG) from mycobacterium (Graham et 
al., 2003). Biosynthesis of the phosphodiester bond and lactate moiety of F420 is 
through GTP-activated (S)-2-phospholactate (Graupner and White, 2001) to form 
F420-0. Subsequent steps in the maturation of F420 include the condensation of multiple 
glutamates linked by amide bonds to the γ-carbons; except in Methanococcus 
jannaschii where the 3 glutamate forms amide bonds with the α-carbons (Graupner 
and White, 2003). 
 
The enzymology of F420 biosynthesis in M. bovis has been studied recently 
using genetic methods (Choi et al., 2001; 2002). fbiC gene participates in the earlier 
steps of F420 biosynthesis between pyrimidinedione and hydroxyphenyl pyruvate to 
form FO (Figure 1.5). fbiAB genes are involved in biosynthesis of F420 from its 
precursor FO, which encompasses addition of a phospho-lactate group and 
condensation of glutamate on FO. M. tuberculosis, M. bovis, M. avium, M. leprae, 
Nocardia farcinica, Streptomyces coelicolor, S. avermatilis, Thermobifida fusca, and 
Rubrobacter xylanophilus all have proteins with high homology for full length fbiC as 
shown in multiple amino acid sequence alignment of fbiC with a few representative 
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 organisms (Figure 1.6). However, in Archaeoglobus fulgidus, Methanobacterium 
thermoautotrophicum, Methanococcus jannaschii, Halobacterium sp., Synechocystis 
sp., and Nostoc sp. all have two polypeptides (located adjacent or non-adjacent) 
encoding fbiC (Figure 1.7; Choi et al., 2002). 
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A. fulgidus AF_0797 AF_0798
M. jannaschii MJ0446 MJ1431
M. thermoautrophicanum MTH_1198 MTH_820
M. bovis Mb1208c, fadHMb1205c, PE12 Mb1206c, fbiC Mb1207c
M. tuberculosis
1kb
Rv1172c, PE12 Rv1173c, fbiC Rv1174c Rv1175c, fadH
TB8.4
Figure 1.7 Gene arrangement of fbiC in different bacterial genomes.  
 
Based on evidence in literature, the proposed F420 biosynthesis scheme in 
mycobacteria is described in (Figure 1.5). The fbiC gene (Rv1173 in MTB; Mb1206c in 
M. bovis BCG) encodes an 856-amino acid polypeptide, an FO synthase that is 
responsible for the condensation of pyrimidinedione with hydroxyphenyl pyruvate, likely 
the first committed step in the F420 biosynthetic pathway. Because of the critical role 
played by fbiC in F420 biosynthesis, we have decided to generate an F420-deficient mutant 
via deletion of fbiC Gene. Characterizing the phenotype of F420 deficient mutant under 
different physiological conditions and comparing it the wild type (F420+) mycobacterial 
cells should shed some light on the possible physiologcal role of F420 or F420 dependent 
processes. This is the approach taken in this master’s thesis using Mycobacterium bovis 
BCG (a BSL 2 surrogate for M. tuberculosis) as a model organism.  
 
In line with this, the two main objectives of masters thesis project are to: 
1. Generate an fbiC-KO (F420-deficient) mutant using homologous recombination and 
confirm the fbiC-KO status though  
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 - genetic characterization (using PCR and Southern hybridisation) and  
- phenotypic characterization (measuring cellular F420 levels and sensitivity to PA-
824).  
2. Characterise F420-deficient (fbiC-KO) mutant under nitric oxide and hypoxic stress 
conditions and compare it with F420+ wild type strain.   
















2.1 Bacterial growth media. 
Preparation of complete 7H9 liquid  medium. 
4.7 g of 7H9 Middlebrook broth base (Becton Dickinson, USA) is dissolved in 
900 ml of distilled water by magnetic stirring. 2 ml of 100% glycerol is then added and 
residual glycerol is removed by repeatedly but gently pipetting the medium. After further 
stirring, 2 ml of sterile 25% Tween 80 is added to the medium mixture and stirred until a 
homogenous solution is achieved. This is then autoclaved at 121oC for 10 minutes. The 
mixture is cooled to room temperature, following which 100 ml of sterile ADS (albumin-
dextrose-saline) supplement is added and stirred. The complete medium is then filter 
sterilised and incubated at 37oC overnight to ascertain that the medium is contamination 
free. The medium can then be stored at 4oC for up to one month. 
Preparation of Dubos complete medium. 
6.5 g of Dubos broth powder (Becton Dickinson, USA) is dissolved in 900 ml of 
distilled water and mixed well. Once a homogenous suspension is achieved, 10 ml of 
sterile 50% glycerol is added to the broth and mixed well. 100 ml of Dubos medium 
supplement (Gibco) is then added and mixed well. Finally, the complete medium is filter 
sterilised and stored in a 37oC incubator.   
Preparation of 7H11 agar plates. 
21 g of 7H11 Middlebrook agar powder (Becton Dickinson, USA) is dissolved in 
900 ml of distilled water by magnetic stirring. Once the powder has dissolved, the 
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 mixture is autoclaved at 121oC for 10 minutes. After this, the autoclaved mixture is 
cooled at 55 oC (in a pre-warmed water bath). Upon cooling, 100 ml of sterile OADC 
(oleic acid-albumin-dextrose/glucoe-saline) supplement and 4 ml of sterile 50% glycerol 
are sequentially added and stirred for about 5 minutes. Plates can then be prepared in a 
Class II BSC, each containing 24 ml of molten agar. Solidified agar plates can be stored 
at 4oC for up to 3-4 months. 
Preparation of ADS and OADC supplements. 
ADS supplement is prepared by dissolving 8.1 g of sodium chloride (NaCl) in 
approximately 500 ml of distilled water by magnetic stirring, followed by 50 g of Bovine 
Serum Albumin  fraction V powder (BSA, Difco) and 20 g of D-glucose powder. Upon 
obtaining a homogenous solution, the solution is topped up to 1 litre and filter sterilised. 
OADC is commercially available from BD Scientific. 
Preparation of Luria-Bertani (LB) broth – liquid medium 
25 g of LB broth powder (Becton Dickinson, USA) is added to 1 litre of distilled 
water and magnetically stirred. Following this, the medium is autoclaved at 121oC for 15 
minutes. 
Preparation of Luria-Bertani (LB) agar – solid medium 
40 g of LB agar powder (Becton Dickinson, USA) is added to 1 litre of distilled 
water and magnetically stirred until all the powder is dissolved. Following this, the 
medium is autoclaved at 121oC for 15 minutes. 15 ml of agar is poured into each plate. 
Masters Thesis                                                                                                        34
 Plates are allowed to cool at room temperature, after which they are wrapped with cling 
film and stored at 4oC. 
 
2.2 Bacterial growth conditions and reagent preparations. 
Growing Mycobacterium bovis BCG in 7H9 complete medium. 
Seed stock of BCG (adjusted to OD 1.0) is inoculated into 7H9 complete medium 
in a 1 litre plastic roller bottle (Corning) at 37oC under slow rolling. The working OD at 
the time of inoculation is hypothetically 0.02, but can vary slightly (± 0.005). 
Experimental work usually requires bacteria to be grown to mid-log phase OD (between 
0.4 and 0.6) unless otherwise stated. 
Growing Escherichia coli in Luria-Bertani broth. 
For all experiments involving E.coli, a 1 in 100 inoculation of seed stock is made 
and grown to required turbidity unless otherwise stated. 
Growing bacteria with antibiotics (added prior to inoculation). 
Mycobacterium bovis BCG mutants are grown with  75 µg/ml Hygromycin and/or  25 
µg/ml Kanamycin.  Escherichia coli is grown with 150 µg/ml Hygromycin or 50 µg/ml 
Kanamycin.  
Antibiotic preparation. 
Hygromycin stock 50 mg/ml is commercially available from Roche. Kanamycin (Sigma 
Aldrich) stock at 50 mg/ml in sterile distilled water is prepared in-house. 
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 50 mM stock of Isonicotinic acid hydrazide (Isoniazid or INH, Sigma Aldrich) is 
prepared in 90% dimethlysulphoxide (DMSO) and stored at -20oC. 
50 mM stock of PA-824 is prepared in-house as described in Stover et al., 2000. 
5 mM stock of Rifampicin (RIF, Sigma Aldrich) is prepared in 90% DMSO and stored at 
-20oC. 
*400 µM working solutions of INH as well as PA-824 and 40 µM of RIF are prepared in 
7H9 medium for the experiment. 
Reagent preparation. 
Sodium nitrite (NaNO2, Sigma Aldrich) powder is dissolved in distilled water to a 
concentration of 1 M and filter sterilised. 
X-gal (5-bromo-4-chloro-3-indolyl- beta-D-galactopyranoside, Sigma Aldrich) stock 
solution of 40 mg/ml is prepared in dimethylformamide (DMF) and stored at 4oC. Only 
40 µg/ml is required in experiments. 
Methylene blue (Sigma Aldrich) stock solution of 500 mg/ml is prepared by dissolving 
powder in distilled water.   
2% Glucose (Fisher) and 0.8% NaCl (Sigma Aldrich) supplement is prepared by 
sequentially dissolving the respective powders in distilled water. The solution  is then 
filter sterilised and stored at 4oC. 
All PCR reagents were purchased from Qiagen and restriction enzymes from New 
England Biolabs and stored at -20oC. 
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 50% sucrose is prepared by dissolving required amount of sucrose crystals (Fisher) in 
distilled water and stored at room temperature. 
 
2.3 Preparation of glycerol stocks of  bacteria. 
E. coli. Overnight-grown culture is aliquoted into 1.8 ml cyrotubes (Nunc) and 
added with 15% glycerol for storage at -80oC. M. bovis BCG. Late-log phase culture (OD 
0.6 ~ 1.0) is harvested by centrifuging at 4000 rpm for 20 minutes. The resulting 
supernatant is discarded, and the pellet re-suspended in an appropriate volume of 
stocking medium (7H9 complete medium with 15% glycerol) to prepare a culture re-
suspension of OD 1.0. 1 ml of this re-suspended culture is then pipetted into 1.8 ml 
cyrotubes, placed in a cardboard storage box and stored at -80oC. Information of all 
bacterial strains, plasmids and primers used in this project can be found in Table 2.1.  
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 2.4 Construction of  the suicide vector/plasmid. 
The strategy employed to achieve this is a double homologous crossover method 
to drive allelic exchange and cause mutation in the wild type genome. This technique has 
been described in Mycobacterium tuberculosis Protocols, Humana Press (2001). The 
vectors used (pYUB854 and pGOAL17) are described in Table 2.1. 
Cloning of 5` fbiC fragment  and 3` fbiC fragment  into pCR 2.1-TOPO vector. 
Taq Polymerase chain reaction (PCR) is used to amplify 5` fbiC  and 3` fbiC  (+ 
100 kb upstream region per fragment) using the genomic DNA of Mycobacterium 
tuberculosis H37Rv as template (in-house preparation) under the following conditions: 
Step 1: 95oC for 3 minutes (heating) 
Step 2: 95oC for 20 seconds(denaturing)   
Step 3: 57oC for 30 seconds (annealing) 
Step 4: 72oC for 90 seconds (elongation) 
Step 5: 72oC for 5 minutes (final extension) 
Step 6:   4oC at infinity* 
 *for overnight preservation of PCR products.  
The PCR recipe used is as follows (primer details in Table 2.1): 
DNAse and RNAse-free distilled water – 13.5µl 
10x buffer  (Qiagen)                                  - 2.5 µl 
MgCl2 solution (25 mM)                          - 0.5 µl 
Forward primer (10 µM stock)                 - 0.5 µl 
Reverse primer (10 µM stock)                  - 0.5 µl 
dNTPs (10 µM stock)                               - 1.0 µl 
Q-solution                                                 - 5.0 µl 
H37Rv genomic DNA (200 ng stock)      – 1.0 µl  
Taq polymerase  (20000 units/ul)             - 0.5 µl 
                                                                   25.0 µl   
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   Following PCR, the products are analysed by 1% agarose gel electrophoresis. 
PCR products are mixed with 5x concentrated loading dye (Biorad) to a ratio of 4 : 1prior 
to loading. Samples are electrophoresed at 120 V and 400 A for 45 minutes. The gel 
containing samples, along with its tray is placed in a chamber for exposure to UV rays. 
The image of the gel is then displayed via the GeneSnap® software on the computer 
monitor connected to the UV chamber (Syngene) and then photographed. The 5` fbiC 
fragment yields a 1017 bp product whereas the 3` fbiC fragment yields a 970 bp product. 
A gel-excision syringe is used for excising the product of interest from the gel and this is 
put into a pre-weighed Eppendorf tube. Using the standard Qiagen® protocol, gel-excised 
PCR product purification is carried out. As ligation of PCR products into pCR 2.1-TOPO 
is mediated by DNA Topoisomerase I, no prior restriction digestion of the vector is 
required. The recombinant pCR 2.1-TOPO vector is transformed via ‘heat-shock’ 
treatment into E.coli TOP 10 competent cells (Invitrogen). Briefly,  the ligated product is 
added to E.coli TOP 10 inoculum and placed on ice for 5 minutes and then transferred to 
a 42oC water bath for 90 seconds. Immediately after, the tube is transferred back to ice 
for a 2-minute incubation. The contents of the tube are then recovered in either LB broth 
or S.O.C medium (Invitrogen) and transferred to a 5 ml U-bottom tube for incubation at 
37oC under shaking for 1hour. Following this, culture is plated on LB agar containing 
Kanamycin and incubated at 37oC. Recombinant colonies are picked and the plasmid is 
purified using the Qiagen® Miniprep kit. After confirmation via gel electropheresis and 
quantification, the insert-containing vector  is then submitted for sequencing. All DNA 
ligation reactions in this project are carried out using the T4 Ligase Reaction Kit (Roche) 
at room temperature as per the manufacturer’s instructions.  
Masters Thesis                                                                                                        40
 Digestion of pYUB854 vector and cloning of 5` fbiC and 3’ fbiC. 
pYUB854 vector (Dr. Srinivasa Rao) is digested with AflII and XbaI to insert the 
purified 5` fbiC fragment and then after, HindIII and XhoI to insert the 3’ fbiC fragment 
for generating pYUB-5`-3`fbiC.    
Insertion of the PacI cassette into pYUB-5`-3`fbiC. 
The 6 kb PacI cassette in pGOAL17 contains 2 important genes, namely lacZ and 
sacB that are used for secondary selection of M. bovis BCG transformants. lacZ encodes 
β-galactosidase which can metabolise X-gal to give a blue coloured appearance. SacB 
leads to cell death when grown on sucrose-containing medium due to the intracellular 
accumulation of polymers. Both pGOAL17 and pYUB-5`-3`fbiC are digested with the 
PacI enzyme and the resulting 6kb fragment from pGOAL17 is purified and inserted into 
pYUB-5`-3`fbiC to generate the suicide plasmid, pYUB-5`-3`fbiC-PacI. 
 
2.5 Transformation of  pYUB-5`-3`fbiC-PacI  into Mycobacterium bovis BCG. 
Competent cells for transformation are prepared by harvesting mig-log phase cells 
via centrifugation at 4000 rpm for 20 minutes. After discarding the supernatant, the cell 
pellet is re-suspended in an equal volume of buffer containing 0.05% Tween 80 and 10% 
glycerol with a sterile serological pipette. This is repeated 3 times. About 1 µg of pYUB-
5’-3’fbiC-PacI is required to transform 200 µl of highly concentrated re-suspended cells 
(in wash buffer). Prior to electroporating the suicide vector into the cells, the plasmid is 
exposed to ultraviolet irradiation. In order to do this, 1 µg of plasmid is pipetted onto a 
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 clean Petri dish and placed in a UV cross linker (UVP Laboratory Products) for about 
550 – 700 s for greater efficiency of transformation (laboratory observation). 200 µl of 
the re-suspended cells is added to a 0.2 cm electrocuvette (Biorad), followed by the 
irradiated suicide vector and mixed well using a sterile pipette tip and placed in a pulsing 
chamber (Biorad) and subjected to a single pulse of 2.5 kV. This entire process is 
represented in Figure 2.1. After electroporation, the transformed cells are recovered in 5 
ml of 7H9 complete medium (in 50 ml centrifuge tubes to allow ample aeration) and 
incubated at 37oC under shaking. This is done over a 20-23 hour period to allow one 
generation time for the transformed cells to recuperate. At the end of the recovery period, 
the transformed cells are centrifuged at 4000 rpm for 10 minutes. After this, the 
supernatant is discarded and the pellet is re-suspended in 1ml of 7H9 complete medium. 
Re-suspended cells are plated onto 7H11 agar with OADC supplement containing X-gal, 




































































Figure 2.1 A schematic representation of the strategy used for generating the suicide plasmid. 
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 2.6 Complementation of F420- deficient mutants with pMV306-fbiC-Kan.  
Intact fbiC gene from pMV306-fbiC-Hyg (Manjunatha et al., 2006) is first sub-
cloned into pMV306-Kan via restriction digestion with HindIII and XbaI and confirmed 
via gel electrophoresis and sequence analysis using primers 15 and 16 (Table 2.1). Using 
the same method as the KO generation, pMV306-fbiC-Kan is transformed into F420- 
deficient mutants. 
 
2.7 Colony PCR reactions with cytosolic extracts. 
50 µl of culture is pipetted into a sterile 1.5 ml Eppendorf tube and centrifuged at 
13000 rpm for 5 minutes. The resulting supernatant is discarded, and the pellet re-
suspended in equal volume of sterile distilled water. The re-suspended pellet is then 
heated at 95oC for 5 minutes (in a heating block) and centrifuged again at 13000 rpm for 
5 minutes. The final supernatant should contain genomic DNA of the cells which is used 
for colony PCR reactions. PCR conditions and recipe are as given in section 2.4. The 
only difference lies in the conditions set for annealing of the primers to the template 
DNA ;  52oC,  51oC,  55oC and 50oC were used as annealing temperatures for 5’ insertion 
profiling, 3’ insertion profiling, to check for presence of fbiC gene and the Hygromycin 
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 2.8 Genomic DNA isolation and southern hybridisation. 
0.2 M glycine is added to mid-log phase cultures 24 hours prior to harvesting and 
incubated under rolling at 37oC. Cultures are centrifuged  at 4000 rpm for 10 minutes and 
the resulting pellet is re-suspended in 500 µl of SET (sucrose-EDTA-Tris) stock solution. 
500 g/ml of lysozyme (Invitrogen) is added to the re-suspended pellet and incubated at 
37°C for 1 hour in a heating block. After this, the mixture is proportionally transferred to 
two 2 ml microcentrifuge tubes and 100 mg/ml of RNase (Invitrogen) is added to each 
tube. The tubes are then incubated for 30 minutes at 37°C in a heating block. At the end 
of the incubation period, an equal volume of freshly prepared Proteinase-K (Invitrogen) 
solution is added to the tubes and incubated at 55°C for 2 hours in a heating block, 
followed by a 5-minute incubation at 70°C and finally, incubation on ice for 5 minutes. 
Once this is done, an equal volume of phenol:chloroform solution is added to the tubes 
and mixed by inverting the tubes by hand for 5 minutes. The mixture is centrifuged at 
4000 rpm for 10 minutes at room temperature (~25oC) to separate the aqueous phase 
from the solvent/organic phase. The aqueous phase is transferred into fresh 2 ml 
microcentrifuge tubes via pipetting while the solvent phase is discarded into liquid waste. 
This step is repeated with the freshly extracted aqueous phase in 2 ml microcentrifuge 
tubes. An equal amount of chloroform is added to the resulting aqueous phase, mixed by 
manually inversion and centrifuged at 4000 rpm for 10 minutes at room temperature.  
The final aqueous phase is obtained and transferred to a fresh 15 ml Falcon tube. 
The solvent phase is discarded into liquid waste. Absolute ethanol is added to the 
aqueous phase by a factor of 2.5 i.e. 1 ml of aqueous phase requires 2.5 ml of absolute 
ethanol, making the total volume in the tube 3.5 ml. After inverting the tube a couple of 
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 times, a dense bundle of thread should appear, and this is the genomic DNA. Using a 
pipette, the bundle is very carefully transferred to a fresh 1.5 ml microcentrifuge tube and 
left to dry in a 37oC incubator with the lid open for 5-10 minutes. It is important to not 
over dry the genomic DNA. Once all or much of the ethanol has evaporated, 1 ml of 75% 
ethanol is added to the genomic DNA, mixed by inverting the tube and centrifuged at 
13000 rpm for 10 minutes to wash away residual phenol and chloroform.  
The supernatant is discarded and 50 µl of pre-warmed (at 55oC) elution buffer is 
added to the genomic DNA and left overnight in a 37oC incubator for the genomic DNA 
to dissolve.  The remaining aqueous phase: ethanol mixture, on the other hand, is 
transferred to a fresh 1.5 ml microcentrifuge tube and centrifuged at 13000 rpm for 10 
minutes. Subsequent, a pellet should form and this is residual genomic DNA. The pellet 
is washed with 1 ml of 75% ethanol via centrifugation at 13000 rpm for 10 minutes and 
then re-suspended in 50 µl of pre-warmed (at 55oC) elution buffer and left overnight in a 
37oC incubator. The amount of genomic DNA extracted is quantified using 
spectrophotometry and the concentration expressed in units of ng/µl. Following this, a 1 
in 10 dilution of the genomic DNA is made using molecular biology-grade water as 
diluent and analysed by 1% agarose gel electrophoresis over 3 hours at 40 volts and 400 
A. 
Southern hybridisation. 
About 2 µg of genomic DNA is digested in BamHI over a 2-hour period. Following 
this, samples were electrophoresed on 1% agarose. Next, the gel is soaked for 15 minutes 
in several volumes of alkaline transfer buffer at room temperature with gentle agitation. 
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 The solution is changed at the end of the 15-minute period and the gel soaked a further 20 
minutes. The gel is then placed onto a positively charged nylon membrane pre-wet with 
distilled water, with the DNA bands facing the surface of the membrane. The transfer 
process is allowed to occur overnight at room temperature. The membrane is removed 
from the transfer apparatus and placed in a container with DIG Easy Hyb buffer (Roche) 
pre-warmed to 37oC and incubated at the same temperature under gentle agitation for 
about 1 hour. Probes are synthesised according to the following recipe for a 50µl 
reaction: 
PCR 10x buffer (Roche)                                  -   5.00 µl 
Distilled water                                                  - 28.75 µl 
Forward primer (10 µM stock)                         -  5.00 µl 
Reverse primer (10 µM stock)                          -  5.00 µl 
Enzyme mix (Roche, 20000 units/ml)               -  0.75 µl 
DIG label  (Roche)                                             -  5.00 µl 
DNA template (200 ng/ul stock)                        -  0.50 µl 
                                                                              50.0 µl_ 
 
The resulting PCR product  is denatured at 95oC for 5 minutes and immediately 
placed on ice. This will produce single stranded DNA labelled with DIG. After this, the 
probe is transferred to DIG Easy Hyb buffer (pre-warmed to 42oC) to a final 
concentration of 2 µl/ml.The membrane is transferred from incubation at 37oC in DIG 
Easy Hyb buffer to a fresh container. Following this, the DIG-labelled solution is poured 
onto the membrane and left to incubate overnight at 42oC under gentle agitation.  
Following DIG labeling, the membrane is transferred to a fresh container. Into this 
container, a solution containing 2x SSC and 0.5% SDS is added and incubated for 1 
minute. This solution is changed with 2xSSC and 0.1% SDS and incubated for 15 
Masters Thesis                                                                                                        47
 minutes under gentle agitation. Following this, the membrane is washed with 0.1x SSC 
and 0.1% SDS under gentle agitation for 30 minutes. The final wash is with 0.1x SSC 
under agitation for 2 minutes. After the final stringency wash, the membrane is again 
transferred to a fresh container and washed with 1x wash buffer (Roche) for 5 minutes. 
The membrane is then incubated in 100 ml of blocking buffer for 30 minutes under 
gentle agitation. 20 ml of the antibody solution is then poured onto the membrane (after 
discarding the blocking buffer) and incubated for 30 minutes under gentle agitation. The 
membrane is then washed twice with 100 ml wash buffer. Before detection with the 
substrate, the membrane is equilibrated in 20 ml 1x detection buffer under gentle 
agitation. Finally, the NBT/BCIP solution (light yellow) is poured onto the membrane 
and the container placed in a dark place for the colour change reaction to develop. When 
dark purple is observed, the reaction is stopped with distilled water and the membrane 
removed for stripping. For this, the membrane is incubated in dimethylformamide (DMF) 
pre-heated to 60oC under gentle agitation at the same temperature until the dark purple 
colour disappears. The membrane is then briefly rinsed in distilled water and washed 
twice with stripping buffer II at 20 minutes per wash. After this, the membrane is briefly 
equilibrated in 2x SSC before proceeding with the next hybridisation reaction.  
Preparation of reagents used in extraction of genomic DNA and southern hybridisation. 
SET solution is prepared by sequentially adding 25% sucrose, 50 mM EDTA solution 
(Gibco) and 50 mM Tris at pH 8 (Gibco) to distilled water and stirring. 
Alkaline transfer buffer is prepared by adding 0.4 M NaOH and 1 M NaCl to distilled 
water. 
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 Neutralisation buffer II (for transfer to charged membranes i.e. positively charged nylon) 
is prepared by adding 0.5 M Tris-HCl at pH 7.2 and 1 M NaCl to distilled water. 
DIG Easy Hyb  buffer, 10x blocking buffer and DNase and RNase free buffer are 
commercially available from Roche. 
10x SSC solution is prepared by adding 1.5 M NaCl and 0.15 M sodium citrate 
(Na3C3H5O(COO)3) to distilled water and filter sterilising . 
0.1% SDS (Biorad) solution was readily available. 
1x maleic acid buffer is prepared by adding 0.1 M maleic acid and 0.15 M NaCl  to 
distilled water and pH-adjusted to 7.5. 
Washing buffer is prepared by adding 0.1 M maleic acid, 0.15 M NaCl and 0.3% Tween 
20 to distilled water and pH-adjusted to pH 7.5. 
Detection buffer is prepared by adding 0.1 M Tris-HCl and 0.1 M NaCl to distilled water 
and pH-adjusted to 9.5. 
Blocking solution is prepared by diluting 1x working solution of blocking buffer in 1x 
maleic acid to a ratio of 1 : 10. 
Antibody (Anti-DIG-AP conjugate, Roche) solution is prepared by diluting antibody in 
blocking solution to a ratio of 1:5000 with a final concentration of 150 mU/ml. 
Colour substrate solution is prepared by diluting NBT/BCIP stock solution (Roche) in 
detection buffer to a ratio of 1 : 50. 
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 Stripping buffer II is prepared by adding 5 M NaOH and 0.1% SDS to distilled water and 
stirring. 
 
2.9 Estimation of Minimum Inhibitory Concentration 99 (MIC99) values. 
Transparent U-bottom 96-well microtitre plates (Nunc) are used for this 
experiment. 50 µl of 7H9 complete medium is first added to each well using a multi-
channel pipette. A 1 in 2 serial dilution of the drugs is the made across the plate, from left 
to right. This method allows for replicating an experiment on the same plate. An example 
of one set of results in Figure 2.2 (MIC99 plate). 1 in 2000 dilution of mid-log phase 
culture is prepared in 7H9 complete medium (1 in 10 and then 1 in 200) and using a 
microtitre pipette, 50 µl of this diluted culture is then added to each well in the microtitre 
plate. They are then placed in an airtight container along with a moist C-fold towel (wet 
with sterile distilled water) and incubated at 37oC for at least 10 days before recording 
data. 
 







 Figure 2.2 MIC99 evaluation of drug sensitivity by observation of cell pellet formation. 
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 2.10 In vivo NO release assay in M. bovis  BCG cells. 
This procedure is described in Singh et al., 2008. Briefly, early log-phase M. 
bovis BCG cells are incubated with the DAF-FM diacetate dye (Invitrogen, Molecular 
Probes) at a concentration of 10 µM for one hour at 37o C. Cells labelled with the dye are 
then harvested by centrifugation and submitted to one washing step to remove unbound 
probe. Following this, the cells are re-suspended in fresh 7H9 complete medium and 
incubated for an additional one hour. 100 µl of cells is incubated with PA-824 at various 
concentrations in a 96-well plate and fluorescence is measured at different time points 
using a BMG Labtech fluorimeter (fluorescence excitation and emission maxima are 495 
nm and 515 nm, respectively). 
 
2.11 Analysis of cellular cofactor F420 levels in crude cell extracts. 
This procedure is described in Guerra-Lopez et al., 2008. Briefly, mid to late-log 
phase (OD 0.5 to 1.0) cultures are transferred to sterile 50 ml centrifuge tubes and 
centrifuged at 4500 rpm for 15 minutes. The resulting supernatant is discarded, and the 
pellet re-suspended in an equal volume of  0.9% NaCl and centrifuged at 4500 rpm for 15 
minutes after which the supernatant is discarded, the pellet retained and re-washed. The 
pellet is then re-suspended in 3 ml of the extraction buffer and  incubated in boiling water 
(100oC) for 15 minutes. The mixture if then placed on ice for 10 minutes and then 
transferred to a high-speed centrifuge tube (Sorvall). After balancing the tube with a 
blank, the mixture is centrifuged at 47, 000 g for 20 minutes and the temperature of the 
machine is set to 4oC. The pellet is discarded and the supernatant transferred to a fresh 15 
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 ml Falcon tube. 2 ml of this supernatant is transferred to another 15 ml Falcon tube 
containing an equal volume of isopropanol. This mixture is vortexed at high speed and 
transferred to a fresh high-speed centrifuge tube and again, centrifuged at 47, 000 g for 
20 minutes. The supernatant is then carefully transferred to a new 15 ml Falcon tube. 
Using a quartz cuvette with a diameter of 1 cm and fluorimeter (Spectramax M2), 
fluorescence of the supernatant-alcohol mixture is measure at an excitation wavelength of 
390 nm and emission wavelength of 460 nm. Three readings per sample are recorded. 
Preparation of wash and extraction reagents (all sterile filtered following preparation 
and stored at 4oC). 
0.9% sodium chloride (NaCl) solution is prepared by dissolving NaCl crystals in distilled 
water. 
50mM disodium phosphate (Na2HPO4, Fw = 141.96) solution is prepared by dissolving 
anhydrous powder in distilled water in a reagent bottle. 
50mM potassium dihydrogen phosphate (KH2PO4, Fw = 136.09) solution is prepared by 
dissolving powder in distilled water. 
Extraction buffer is prepared by adding required volumes of 50 mM Na2HPO4 and 50 




Masters Thesis                                                                                                        52
 2.12  Nitrosative stress experiment. 
This procedure is implemented as described in Darwin et al., 2003. Briefly, 20 ml of 
mid-log phase culture is harvested via centrifugation. The resulting supernatant is 
discarded, and the pellet re-suspended in 7H9 complete medium with glucose and NaCl 
supplement (without albumin) at pH 6.8 to make a culture of OD 1.0.  The experimental 
setup is as follows (4  tubes per strain): 
Tube Contents 
1 
7H9 medium + glucose and NaCl supplement at pH 6.8 + 15 µl of sterile dH2O + 
100 µl of OD 1.0 culture 
2 
7H9 medium + glucose and NaCl supplement at pH 5.5 + 15 µl of sterile dH2O + 
100 µl of OD 1.0 culture 
3 
7H9 medium + glucose and NaCl supplement at pH 5.5 + 1.5 mM NaNO2 + 7.5 µl 
of sterile dH2O + 7.5 µl of sterile 1 M NaNO2 solution (1.5 mM NaNO2) + 100 µl of 
OD 1.0 culture 
4 
7H9 medium + glucose and NaCl supplement at pH 5.5 + 15 µl of sterile 1 M
NaNO2 solution (3.0 mM NaNO2) + 100 µl of OD 1.0 culture 
 
At designated time points, 1 in 10 dilutions are made in a 96-well microtitre plate 
using 7H9 medium with glucose and NaCl supplement (without albumin) at pH 6.8 and 
plated on 7H11 medium using 50 µl of inoculum per quadrant. CFUs are counted after at 
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 2.13  Exposure of M. bovis BCG to hypoxic conditions. 
Gradual oxygen depletion (Wayne model) experiment. 
This procedure has been described in Wayne et al., 1996. Briefly, mid-log phase 
cultures grown in 7H9C are passaged in Dubos complete medium and again, grown to 
mid-log phase. The Dubos-grown cultures are then harvested via centrifugation. After 
discarding the supernatant, the resulting pellet is re-suspended in fresh Dubos complete 
medium to an OD of 0.005.  17 ml of this culture is added to pre-sterilised standard 
Wayne tubes to maintain a HSR of 0.5. One tube per strain is required as control, with 51 
µl of methylene blue as a marker for oxygen depletion. At designated time points, OD600 
is measured using a specialised spectrophotometer (Biochrom Libra S12). The cultures 
are then used for making 1:10 serial dilutions on a 96-well plate in Dubos complete 
medium and plated on 7H11 agar plates with OADC supplement.  
Anaerobic shiftdown  experiment. 
Mid-log phase cultures grown in 7H9 complete medium and Dubos, respectively 
are diluted to OD 0.1 in fresh media. 1 ml of diluted cultures is then aliquoted into wells 
in a 24-well tissue culture plate (Nunc), placed in an airtight container with an anaerobic 
condition generator (Oxoid) and an indicator strip containing methylene blue and stored 
in an anaerobic chamber. At different time points,  serial dilutions are made and plated on 
7H11 medium with OADC supplement. CFUs for both experiments are counted after at 
least 14 days of incubation at 37oC. 
* All plating of bacteria is done in duplicates.





























 Based on the literature review of the cofactor F420 biosynthetic pathway, fbiC 
plays a critical role in F420 biosynthesis. Generation of F420 deficient strain by deletion 
of a chromosomal copy of fbiC gene in mycobacterium is an important tool in 
understanding the role of F420 in different physiological conditions.  
 
3.1 Generation of the F420-deficient M.bovis BCG mutant. 
Using a two step homologous recombination strategy (Parish and Stoker, 
2000), we have generated a BCG∆fbiC strain as shown schematically in Materials and 
Methods Figure 2.1. This strategy involves a two-plasmid cloning system, namely, 
first cloning of 5` and 3` fbiC fragments on either side of the Hygromycin cassette in 
pYUB854 plasmid, a non-replicating delivery vector in mycobacterium. Secondly, 
cloning of PacI cassette from pGOAL17 containing lacZ and sacB genes into plasmid 
pYUB-5`-3` fbiC. lacZ is used for blue/white selection and sacB for negative 
selection in presence of sucrose (Jackson, 2001).  A two-step strategy means that from 
the electroporation alone, single cross-over (SCO) is required to happen and in the 
second step selected for double cross-over. SCO may either be a 5` recombination 
event or 3` recombination event as shown in Figure 3.1. Single cross-over mutants are 
specifically selected as Hygromycin resistant and form a blue coloured colony on X-
gal containing plates, and these would be mero-diploid for fbiC gene. In the second 
step, the second recombination event is favoured by sucrose negative selection. Thus, 
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 double cross-over mutants are phenotypically selected as Hygromycin resistant, form 
a white-coloured colony on X-gal containing plates and sucrose insensitive.   
 
WT genome fbiC (Rv1173) Rv1174cRv1172c fadH (Rv1175c)
DCO Rv1174cRv1172c fadH (Rv1175c)Hyg cassette
(b) 3` SCO fbiC (Rv1173)
(a) 5` SCO fbiC (Rv1173)
a bRecombination with suicide 
vector





  Figure 3.1 The different recombination events leading to an insertion at the 5` end (a), 3`
end (b) or a disruption in fbiC.  Colony PCR analysis: 
 We screened nearly 10 recombinant colonies (all Hygromycin resistant, 
blue/white colonies) for further characterisation by colony PCR as described in the 
previous chapter (Material and Methods).  The primer combinations as well as 
sequences used for this have also been listed in the previous chapter as well as Figure 
3.2. As PCR “product A” is amplified using fbiC-5`-RC-FP (primer 7) and 
Hygromycin internal hygR2 (primer 6), we would expect this product to be amplified 
in double cross-over mutants and 5`-single cross-over mutants only. Similarly, for 
PCR “product B” amplified using Hygromycin internal hygF (primer 5) and fbiC-3’-
RC-RP (primer 8), we would expect this product to be amplified in double cross over 
Masters Thesis                                                                                                        57
 mutants and 3`-single cross-over mutants only. Hence, if we observe both PCR 
products A and B, it represents a double cross-over event in the mutant, at the same 
time, an fbiC internal fragment should be absent and Hygromycin internal fragment 
should be present.  One of such fbiC-KO colony (BCG∆fbiC) PCR analysis along 
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Figure 3.2 Confirmation of fbiC-KO by PCR. The schematic diagram KO-
confirmation PCR (top panel). Bottom panels agarose gel elecrophoresis of PCR 
products from wild type and BCG∆fbiC strains. Numbers ndica  with coloured 
arrows in the schematic diagram represent primers in Table 2 1. (M  1 kb plus DNA 
ladder (Invitrogen), A = 5´ insertion profiling (1 kb pro
profiling (1.017kb product), C = fbiC internal profiling (1
resistance cassette profiling (550 bp product), E = wild type
product) for Southern hybridisation. Amplicons shown in col
the probed used for Southern hybridisation (see Figure 3.3). 
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 The organisation of genes near fbiC are highly conserved between M. bovis 
BCG and M. tuberculosis H37Rv (Figure 3.3). Nucleotide sequence identity is > 96%. 
Hence, using the suicide delivery vector pYUB-5’-3’-fbiC-PacI constructed in this 
study, we have recently generated an M. tuberculosis H37Rv fbiC deletion construct. 
Deletion of fbiC in H37Rv∆fbiC strain was also confirmed by Southern blotting as 
shown below. (Note: Characterisation of H37Rv∆fbiC for all other phenotypes is in 
progress in the group).  
Confirmation of fbiC-KO by Southern hybridisation: 
In order to reconfirm the deletion of fbiC in the BCG∆fbiC and H37Rv∆fbiC 
strains, genomic DNA from fbiC-KO and wild type strains were digested with BamHI 
and used for Southern blotting. The blot was sequentially probed with three PCR 
products: fbiC 5`-fragment (PCR product E), Hygromycin internal fragment (PCR 








M. bovis BCG 
WT           BCG∆ fbiC
6.4 kb 






Figure 3.3 Southern hybridisation profiles of wild type BCG and MTB and their 
respective fbiC-KO mutants. The letters on the right of the panel correspond to PCR 
amplicons used as probes for hybridisation (see Fig. 3.5): C = fbiC internal fragment (1.1
kb), D = Hygromycin internal fragment (550 bp product), E = 5` fbiC fragment (1 kb
product). 
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 As illustrated in Figure 3.2, fbiC has an internal BamHI site towards the 3`-end 
of the gene.  Thus, in wild type BCG and MTB strains, the 5`-fbiC fragment probe 
hybridised to an expected, approximately 5 kb BamHI genomic DNA fragment. 
Whereas in the BCG∆fbiC and H37Rv∆fbiC strains, the same probe hybridised to a 
6.4 kb fragment as the fbiC internal Bam HI site is lost due to gene deletion (Figure 
3.3, top panel). With this probe, there seems to be a non-specific hybridisation to a 
smaller fragment which appears in both wild type and mutant strains. By using fbiC 
internal fragment as a probe, fbiC deletion was confirmed (Figure 3.3, bottom panel). 
Also, as expected, the Hygromycin internal fragment hybridised only in the deletion 
mutants as illustrated in Figure 3.3, middle panel.  
 
 So far, it has been reported that fbiC deletion mutants are either generated 
via transposon mutagenesis (Darwin et al., 2003; Choi et al., 2002) or spontaneous 
PA-824 resistance (Choi et al., 2002, Manjunatha et al., 2006). Both transposon 
mutants as well as spontaneous PA-824 mutants might have secondary unknown 
mutations along with the F420- (F420-deficient) phenotype. Thus, the directed 
BCG∆fbiC strain constructed in this study establishes the non-essentiality of F420 or 
F420-dependent pathway(s) for mycobacterial survival under normal in vitro 
conditions.    
Complementation of the BCG∆fbiC mutant with M. tuberculosis fbiC: 
BCG∆fbiC mutant was complemented with pMV306-fbiC-Kan, wherein the 
M. tuberculosis fbiC gene along with a 1000 bp upstream fragment has been cloned 
into pMV306-Kan, which is an integrative plasmid. Thus, the regulation of 
complemented fbiC gene expression is identical to that of the wild type.  
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 3.2 Analysis of cellular levels of cofactor F420 in crude cell extracts. 
The BCG∆fbiC mutant is incapable of biosynthesising cofactor F420. 
After having confirmed the disruption of the fbiC gene via PCR and Southern 
hybridisation, we wanted to next ascertain that this mutant strain (BCG∆fbiC) was 
truly incapable of biosynthesising cofactor F420. In order to do this, cofactor FO and 
F420 levels were measured in the BCG∆fbiC mutant, wild type and the mutant strain 
complemented with MTB fbiC by analysing crude cell extracts by fluorescence output 
(390 nm excitation and 460 nm emission wavelengths) as described in Guerra-Lopez 
et al.,  2007. As shown in Figure 3.4, greater relative fluorescence was observed in 
wild type BCG cells (89.4±0.8) relative to the BCG∆fbiC mutant (18.8±0.6), and this 
difference is significant. Furthermore, the relative fluorescence units (RFUs) in the M. 
tuberculosis fbiC complemented BCG∆fbiC strain (113.1±0.7) is at least as good as 
the wild type. Limitations of this method are firstly the fluorescence measured can not 
distinguish between F420 and FO; secondly, since the fluorescence measured is from 
crude extract, the relative fluorescence measured is bound to be influenced by cellular 
components other than F420. Most likely, relative fluorescence units observed with 
























      Figure 3.4 Analysis of cellular cofactor F420 levels. 
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 3.3 The F420-deficient mutant is resistant to the bicyclic nitroimidazole PA-824. 
The current TB drugs are mostly effective against actively replicating bacilli 
and largely ineffective against persistent forms. This has led to a recent interest to 
develop new TB drugs that target persistent bacilli (Sacchettini et al., 2008). Bicyclic 
nitroimidazoles such as PA-824 and OPC-67683 form an interesting class of 
antitubercular compounds as they have inhibitory activity against both actively 
replicating and hypoxic non-replicating (NRP-2) MTB (Stover et al., 2000; Barry et 
al 2004; Matsumoto et al., 2006). PA-824 is a prodrug whose bioreductive activation 
has been shown to be dependent on Rv0407 which encodes an F420-dependent 
glucose-6-phosphate dehydrogenase (FGD1) (Stover et al., 2000). Resistance to PA-
824 has been shown to be by loss of a specific glucose-6-phosphate dehydrogenase 
(FGD1) or its deazaflavin cofactor F420 which together provide electrons for reductive 
activation of this class of molecules (Choi et al., 2002; Manjunatha et al.,2006).  
 
Since F420 is an essential component of PA-824 mechanism of action, we 
tested the sensitivity of the BCG∆fbiC mutant to PA-824 along with wild type BCG 
cells and fbiC-complemented strains in order to confirm the F420-deficient phenotype 
attributed to fbiC deletion. The broth dilution method was used to determine the 
minimal inhibitory concentration-99 (MIC99) as described in the previous chapter. 
MIC99 is defined as the minimum concentration at which no visible growth is 
observed after 2 weeks of incubation with wild type, BCG∆fbiC or complemented 
strains with the drugs mentioned in the previous chapter. The typical MIC99 profile of 
these strains (from replicated experiments) is shown in Table 3.1. 
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 Drugs                                    Bacterial strains
BCG wt BCG∆fbiC BCG∆fbiC:: fbiC (comp) 
INH 0.8µM 0.8µM 0.8µM
RIF <0.05µM <0.05µM <0.05µM









D Table 3.1 Drug sensitivity profiles of the wild type BCG, BCG∆fbiC and its 
complemented strain as evaluated by MIC99.  
As shown previously (Choi et al., 2002, Manjunatha et al., 2006), the F420-
eficient mutant is completely insensitive to PA-824. However, the fbiC-
omplemented strain has regained PA-824 sensitivity like wild type (Table 3.1), 
uggesting that the BCG∆fbiC mutant is incapable of F420 biosynthesis. However, all 
hree strains are equally sensitive to Rifampicin and Isoniazid, whose mode of action 
s independent of F420. Therefore, this drug sensitivity method acts as a rather 
ffective diagnostic tool for ascertaining the genotype and hence, phenotype of the 
CG∆fbiC as well as fbiC-complemented mutants.   
The BCG∆fbiC  mutant is  incompetent for PA-824-mediated in vivo NO release. 
For bioreductive activation of PA-824, both FGD1 and F420 are necessary, 
long with an additional accessory protein - an F420-dependent nitro-reductase (Fnr) or 
dn (Deazaflavin-dependent nitroreductase) (Manjunatha et al., 2006).  Based on the 
metabolite profiling of PA-824 and its analogues by Ddn, it has been recently shown 
that bicyclic nitroimidazoles act as nitric oxide (NO) donors (Figure 3.5, Panel A), 
and NO release from various PA-824 derivatives correlate well with the anaerobic 
killing of MTB (Singh et al., 2008). Further, in the same study, the release of 
intracellular NO in mycobacterium with PA-824 has been demonstrated with 
diaminofluorescein (DAF-FM) that fluoresces specifically in the presence of NO 
(Kojima et al., 1998). 
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 In order to test whether BCG∆fbiC which is resistant to PA-824 is incapable 
of PA-824-derived NO production, we preloaded wild type BCG, BCG∆fbiC and its 
complemented strain with DAF-FM diacetate and treated with PA-824. DAF-FM 
diacetate is an intracellular NO probe, which is converted to DAF-FM by esterase 
enzymes present in the cells (Figure 3.5, Panel B). This experiment measures the 
release of NO from cells over time using fluorescence generated by the covalent 
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Figure 3.5 Analysis of PA-824-mediated in vivo NO release (A). The generation of 
nitric oxide in this process (B) is directly reflected by the binding of DAF-FM to NO 
and the resulting fluorescence (C).  
 
The results in Figure 3.5 (Panel C) show a time and concentration dependent 
intracellular release of NO in BCG wild type cells but not in the BCG∆fbiC strain. 
However, the wild type phenotype is restored to the complemented strain; rendering it 
capable of bioreductive activation of PA-824 and releasing NO as a result. This 
confirms that BCG∆fbiC is resistant to PA-824 and is incapable of bioreductive 
activation of PA-824 to generate nitric oxide.    
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 3.4 F420-deficient mutants are hypersensitive to NO. 
The main site of MTB infection is the lung (>80%), where it infects alveolar 
macrophages (Smith, 2003). The bacillus is phagocytosed by the macrophage and is 
found in membrane-bound vesicles known as 'phagosomes‘. The infectious 
phagosome does not mature, but remains in a state similar to the 'early endosome‘. 
The phagosome does not acidify or fuse with lysosomes and hence, is unable to 
facilitate the killing of the organism (Kaufman, 2001). Subsequent survival and 
multiplication within macrophages is a key feature of mycobacterial virulence in vivo 
(Kaufmann, 2001). Generally, macrophages phagocytose invading bacteria and kill 
them by a number of mechanisms, namely production of reactive oxygen species 
(ROS), reactive nitrogen species (RNS), lysosomal enzymes, antimicrobial peptides 
etc (Smith, 2003; Boshoff and Barry, 2005). RNS generated by the host enzyme 
inducible nitric oxide synthase (iNOS) is very critical for controlling infection of 
MTB in mice (MacMicking et al., 1997). MTB actively resists killing by 
macrophages, a property that confers invasiveness on the microorganism to be a 
successful pathogen (Kaufmann, 2001; Warner and Mizrahi, 2007). 
 
Earlier, by genome wide transposon mutagenesis and screening for MTB 
mutants hypersensitive to killing by NO, Darwin and colleagues (2003) identified 
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 those involved in the proteosomal machinery, DNA repair and fbiC (Darwin et al., 
2003; Darwin et al 2005). In order to test whether BCG∆fbiC is hypersensitive to NO 
stress, we exposed wild type BCG cells and BCG∆fbiC to acidified (pH 5.5) sodium 
nitrite (1.5mM and 3.0mM) for 1 and 4 days. When NaNO2 is exposed to acidic 
conditions (such as pH 5.5), protonation occurs and this leads to the generation of 
hydroxy NO2 (HNO2). Further on, dissociation of this product produces NO and other 
nitrogenous radicals (Ehrt et al., 1997). At different time points, the stressed cells 






















Wt BCG + 1.5mM NaNO2
Wt BCG + 3.0mM NaNO2
fbiC-KO, pH6.8
fbiC-KO, pH5.5
fbiC-KO + 1.5mM NaNO2
fbiC-KO + 3.0mM NaNO2









Figure 3.6 Effect of nitrosative stress conditions on the BCG∆fbiC mutant (*indicates the 
complete absence of CFUs on plates). 
As shown in Figure 3.6, the fbiC-KO mutant exhibits hypersensitivity to 
nitrosative stress in comparison to the wild type and growth is greatly attenuated by 
day 4. Compared to the wild type, the F420 mutant is nearly 1.5 log CFUs/ml more 
sensitive to 3.0 mM NaNO2 treatment by day one. Then, at 1.5 mM NaNO2 on day 4, 
we were unable to see any CFUs with the F420 -deficient mutant, whereas under 
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 similar conditions nearly 103 CFUs were observed with wild type BCG cells. There 
certainly appears to be a clear 3 log difference in terms of CFUs/ml between the wild 
type and fbiC-KO strains of BCG. However, there is no difference between wild type 
BCG and BCG∆fbiC in growth phenotype under acidic conditions. Effectively, this 
experiment reconfirms the phenotype for fbiC transposon insertion mutant as 
observed earlier (Darwin et al., 2003). 
   
  Mycobacterium has several mechanisms to resist RNI damage. MTB is 
known to encode enzymes that break down RNI species such as peroxynitrite 
reductase, AhpC (Bryk et al., 2000). Others help to degrade damaged macromolecules 
like proteins (Darwin et al., 2003) or DNA (Darwin et al., 2003, Darwin and Nathan, 
2005). Many other genes have been identified in mycobacterium that play a role in 
protection against RNI like noxR, hmp etc. (Ruan et al., 1999; Hu et al., 1999; 
Crawford and Goldberg, 1998). MTB Ddn (Rv3547) has been shown to denitrosylate 
bicyclic nitroimidazoles such as PA-824 (Singh et al., 2008). MTB has four 
homologues of Ddn and these are highly conserved among actinomycetes. This 
enzyme family may have evolved to perform denitration of nitrated macromolecules 
like DNA, protein etc. as a repair pathway for NO damage. This needs to be explored 
further. The role of Ddn class of enzymes in protection against nitrosative stress was 
corroborated by showing the phenotype of mutants incapable of F420 biosynthesis 
(Figure 3.6; Darwin et al., 2003). Thus, F420-dependent pathways could play a critical 
role in coping with DNA damage through Ddn class of enzymes and/or other 
mechanisms yet to be elucidated. 
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 3.5 Growth phenotype of F420-deficient mutants under hypoxic conditions 
 
MTB is capable of establishing persistent or latent infection in the host by 
using a complex interplay between the host immune response and bacterial survival 
mechanism (Parrish et al., 1998). In the latent infection, MTB adapt to depletion of 
oxygen as well as nutrients and enter a stage of non-replicating persistence (NRP) in 
granulomatous-necrotic lesions (Wayne and Sohaskey, 2001). Several models of in 
vitro persistence have been proposed to mimic the conditions found in human 
granulomas namely oxygen starvation or the Wayne model (Wayne and Sohasky, 
2001), nutrient deprivation (Betts et al., 2002) and Rifampicin-induced persistence 
(Hu et al., 2003). Deprivation of nutrients is likely to take place in human granuloma 
structures; however it not clear whether it would induce bacteriostasis or adaptation to 
survive. The Rifampicin-induced persistence model is simple and mimics what 
happens in humans after the onset of chemotherapy, but the molecular mechanism of 
drug tolerance in mycobacterium is not clear.  
 
Generally, MTB is considered a strict aerobic bacterium; however it can 
survive for a long time in a microaerophilic environment (Wayne and Hayes, 1996). 
Recently, using a hypoxic marker and metronidazole drug treatment, it has been 
shown that MTB resides in hypoxic lesions in higher animal models of disease 
(including nonhuman primates) that form caseous and necrotic granulomas (Via et al., 
2008). The best characterised in vitro hypoxia model was developed by Lawrence 
Wayne (Wayne and Hayes, 1996), in which a non-replicating state is induced in 
mycobacteria by gradual depletion of oxygen because of bacterial growth and 
respiration. As no difference in growth pattern is observed between wild type and 
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 fbiC-KO BCG cells when both are grown under standard aerobic in vitro conditions 
(data not shown),  we aimed to investigate the possible role of F420 and/or an F420-
dependent pathway for survival of MTB under non-replicating hypoxic conditions. 
We analysed wild type BCG and BCG∆fbiC strains for survivability using the Wayne 
model of gradual oxygen depletion as well as under rapid oxygen shiftdown 
conditions (anaerobic shiftdown).  
 
In the gradual oxygen depletion experiments, both strains were cultured into 
Dubos medium in tightly sealed tubes with a head-space ratio (HSR) of 0.5. Tubes 
were incubated at 37oC under stirring at 170 rpm, for 34 days. At various time points, 
OD was measured and cultures were plated on 7H11 for CFU counting. As shown in 
Figure 3.7, growth of both wild type BCG and BCG∆fbiC was on par to each other 
until 15 days. However, survival of the mutant is crippled by at least 1.5 - 2 log 
compared to wild type after 26, 29 and 34 days, though having no effect on OD. The 
decrease in CFUs per ml values for the wild type is not as dramatic as it is for the 
BCG∆fbiC strain after 15 days of incubation until the end of the experimental period. 











































Figure 3.7 Growth phenotype of BCG wild type and BCG∆fbiC strains under 
Wayne model. The stages of NRP are also shown.  
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 Rapid oxygen depletion model –“Anaerobic shiftdown” 
In the anaerobic shiftdown model, actively growing aerobic mid-log phase 
cells in 7H9 medium or Dubos medium are diluted to an OD of 0.1 and these cultures 
are then transferred to a 24-well plate and placed in an anaerobic chamber. At 
different time points, cultures are plated on 7H11 medium and incubated at 37oC for 
at least 2 weeks and CFUs per ml are then after counted. Unlike the Wayne model for 
gradual oxygen depletion, the anaerobic shiftdown model does not allow much time 
for cells to alter metabolism per the change in oxygen availability as the cells are 
abruptly transferred to the anaerobic chamber. However, the main advantage of this 
model is that it is time-efficient and we have tried both 7H9C and Dubos media. The 
most striking difference between 7H9C and Dubos medium is the absence of glycerol 
as a carbon source in the latter, and for unknown reasons mycobacteria prefer glycerol 







































Figure 3.8 Survival phenotype of WT and BCG∆fbiC under anaerobic shiftdown 
conditions. * indicates the complete absence of CFUs on plates. 
From the results shown in Figure 3.8, the BCG∆fbiC mutant is unable to adapt 
to anaerobic conditions in both 7H9C as well as Dubos medium as observed from 
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 CFU counts on Days 14 and 19. By day 19, we failed to see any CFUs of the 
BCG∆fbiC strain in both media conditions. Comparing data from day 0 (start of 
experiment) to day 19, there happens to be at least a 7 log reduction in CFUs per ml 
for the BCG∆fbiC strain but only a 3 log reduction for the wild type strain. Significant 
drop in viable bacilli counts of BCG∆fbiC in both the Wayne model of gradual 
oxygen depletion and the anaerobic shiftdown model could either be attributed to 
inability to survive or simply reactivate on agar plates. We can not distinguish 
between these two possibilities, since the viable counts measured in this study are by 
plating and measuring colony forming units. Results from Figures 3.7 and 3.8 suggest 
a possible role for F420 in MTB in the low-redox potential electron-transfer reactions 
that would be associated with anaerobic survival (Bagramyan et al., 2000; Smith and 
Edwards, 1995). 
 
As the complementation of the BCG∆fbiC strain was carried out rather late in 
the course of the project due to technical stumbling blocks, the resulting fbiC-
complemented strain could not be included in NO hypersensitivity and hypoxia 
experiments. This master’s thesis research project highlights the possible 
physiological role of F420 for survival of M. bovis BCG under nitrosative stress and 
hypoxic conditions. Consequently, an apparent non-essential cofactor seems to play a 
significant role for survival of MTB under physiological conditions. Thus, it is not 
surprising that even M. leprae, which has undergone significant reductive evolution 
(Cole et al., 2001) has retained the F420 biosynthetic pathway. However, very little 
information is available on the molecular basis of the role played by F420 in MTB. 
Effectively, this project opens more questions than providing answers on the roles(s) 
of F420 in mycobacterium. 
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 4. CONCLUSION 
 
 F420 (7,8-didemethyl-8-hydroxy-5-deazaflavin derivative) is a unique 
coenzyme with a redox potential of -350 mV. Structurally, it resembles the flavin 
class of molecules, but functionally closer to nicotinamide analogues, as it is involved 
in hydride transfer reactions. This cofactor has an exclusive distribution among 
euryarchaea, halobacteria, some cyanobacteria and in high G+C Gram positive 
actinomycetes. F420 plays an essential role in methanogenesis in methanogenic 
archaeobacteria. All mycobacterial species studied to date have F420 biosynthetic 
genes including M. leprae.  The maintenance of such complex biosynthetic pathways, 
even in M. leprae which has undergone substantial gene decay, strongly suggests that 
F420 plays a vital role in the biology of mycobacteria. Little is known regarding the 
physiological role of coenzyme F420 in mycobacteria. Incidentally F420 is required for 
the activation of a bicyclic nitroimidazole PA-824 and release of nitric oxide in 
mycobacterium. This masters project was designed to generate an F420-deficient 
Mycobacterium bovis BCG mutant through fbiC gene KO. fbiC gene encodes FO 
synthase in mycobacterium (Choi et al., 2002), an important enzyme in F420 
biosynthesis. Further characterizing the mutant under physiologically relevant 
conditions like nitrosative stress and hypoxia and comparing with the wild type cells 
should shed some light on the possible role(s) F420 or F420-dependent reaction(s) under 
these conditions. 
 
F420 or F420 dependent pathway(s) seems to be not essential for mycobacterial 
growth and survival under normoxic 7H9 medium growth conditions (Choi et al., 
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 2002). However, our further experiments revealed that the F420-deficient (fbiC-KO) 
mutant is hypersensitive to NO (nitric oxide). This suggests a possible role for F420 or 
an F420-dependent pathway in protection against nitrosative stres. More recently, 
Purwantini and Mukhopadhyay (Proc Natl Acad Sci U S A (Apr 14 2009); 106 (15), 
6333) described the role of H2F420 in direct non-enzymatic reduction of nitrogen 
dioxide to nitric oxide; MTB is more sensitive to NO2 than NO. Thus, F420 reduced by 
FGD1 seems to play an important role in detoxification of NO2. It is interesting to 
note that on one hand F420 plays a critical role in activation of PA-824 to release nitric 
oxide using Deazaflavin nitroreductase (Ddn), while on the other F420 plays a role in 
protecting mycobacterium against nitrosative stress. Therefore, F420 and/or  possible 
F420 dependent reaction(s) not only provide a protection against nitrosative stress, but 
can also be exploited to inflict such a stress on these organisms for adaptation, which 
needs to be addressed. 
 
Mycobacterial FGD1 (F420 dependent glucose-6-phosphate dehydrogenase) 
catalyzes enzymatic dehydrogenation of glucose-6-P to 6-P-gluconolactone while 
reducing the cofactor F420. The conversion of glucose-6-P to 6-P-gluconolactone is the 
first committed reaction for the pentose phosphate pathway. MTB genome has four 
annotated glucose-6-phosphate dehydrogenases (G6PDs), two are classical NADP+ 
dependent (Rv1121, zwf1 and Rv1447c, zwf2) and the other two are F420 dependent 
(Rv0407, fgd1 and Rv0132c, fgd2) of which FGD1 has been shown to catalyse G6PD 
activity (Purwantini and Daniels, 1996). Interestingly M. leprae has only one 
functional G6PD which is F420 dependent (ML0269c). Role of F420-dependent G6PD 
in the pentose phosphate pathway in Mycobacterium tuberculosis remains to be 
addressed.  
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 It is widely believed that oxygen limitation, amino acid starvation, carbon 
source restriction and variety of host factors are involved in establishing and 
maintaining MTB in a dormant state. Our preliminary experiments revealed F420 
deficient mutants are crippled under hypoxic conditions, suggesting a possible role for 
F420 / F420 dependent enzyme in survival of MTB under hypoxic conditions or during 
reactivation stage. This needs to be further addressed. If demonstrated, F420 
biosynthesis could be an attractive latency target against MTB. Thus, coenzyme F420 
seems to play a role in aspects of metabolism which are considered critical for the 
pathogenesis of this organism by virtue of its role in protection against NO as well as 
survival during non-replicating persistence. Even though this Master’s thesis project 
does not address a specific physiological role for F420 in mycobacterium, it opens up a 
lot of interesting questions. 
 
The clinical management of Mycobacterium tuberculosis in infected patients 
is a challenging problem because of the six-month duration of chemotherapy with 
multiple drugs. This prolonged treatment is essentially attributed to lack of good 
activity of the currently available drugs against latent bacilli. The effective means to 
tackle tuberculosis is targeting persistent bacilli for drug development. We anticipate 
that by understanding the role F420 in non-replicating mycobacterial cells and its role 
in protecting MTB against NO would advance our knowledge of the biology of latent 
tuberculosis and change the way we think about molecular pathways that are critical 
for the pathogenesis of MTB.  
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